CRISPR Therapeutics AG

NASDAQ:CRSP

Biotechnology

Healthcare
$40.19 +2.70%

+$1.43 today

Market cap
$3.90B
Beta
1.70
P/E (TTM)
-9.2
EPS (TTM)
-$5.92
52W Low $43.23High $78.48

Volume 3.97M

Average 1.70M

CRSP Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

CRISPR Therapeutics AGNASDAQ: CRSP

Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026

Depreciation & amortization declines year over year

Q3 FY2026 depreciation & amortization of $4.24M fell 4.4% year over year, behind the -0.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.0% from the prior quarter. Over 3 fiscal years it compounded at -6.9% a year.

Context

  • Depreciation & amortization amounted to 555.0% of revenue in FY2025, up 499.9 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -4.4% toward the trailing-twelve-month pace of -0.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$4.24M-1.0% QoQ
Last fiscal yearDec 2025
$19.48M+1.1% YoY
LTMSep 2026
$18.5M-0.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.4%——
1 year+1.1%——
3-year CAGR-6.9%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
19.48M USD
Year-over-year change
+1.1%
4-year CAGR
+2.1%

Depreciation & Amortization vs competitors

How CRSP compares with its peers on the latest reported figures

  • CRSP's LTM Sep 2026 depreciation & amortization of $18.5M is the 3rd largest of the 7 companies compared; the peer median is $12.75M.
  • Its year-over-year change of -0.9% is the 2nd highest of 7, against a peer median of -8.4%.
  • Depreciation & amortization amounts to 73.5% of revenue for CRSP, versus a peer median of 14.7%.
CRSP Competitors Peer median
Depreciation & Amortization for CRSP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026$56.42M -13.9%+11.5%39.9%
BEAMBeam Therapeutics Inc.LTM Jun 2026$22.24M +1.2%+16.4%14.3%
CRSPCRISPR Therapeutics AGLTM Sep 2026$18.5M -0.9%-6.9%73.5%
RGNXREGENXBIO Inc.LTM Mar 2026$15.52M -3.0%+6.5%17.7%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$9.99M -2.7%+10.7%15.1%
EDITEditas Medicine, Inc.LTM Mar 2026$4.17M -34.0%-5.9%10.8%
DTILPrecision BioSciences, Inc.LTM Mar 2026$2.69M -30.3%-32.6%6.0%
Peer median (excluding CRSP) $12.75M-8.4%+8.6%14.7%

Competitors are the stored peer set for CRSP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income377.66M(650.18M)(153.61M)(366.25M)(581.6M)
Depreciation & Amortization17.95M24.17M19.84M19.26M19.48M
Deferred Income Tax00000
Stock-Based Compensation102.39M97.95M81.03M86.57M72.5M
Change in Working Capital26.86M19.85M(193.59M)156.27M71.88M
Accounts Receivables(161K)305K(200M)175M25M
Inventory(37.51M)0000
Accounts Payables37.51M5.16M(20.25M)044.89M
Other Working Capital27.02M14.38M26.66M(18.73M)1.99M
Other Non-Cash Items14.11M12.47M(14.05M)(38.62M)72.73M
Operating Cash Flow538.97M(495.74M)(260.38M)(142.77M)(345.01M)
Capital Expenditures(81.71M)(37.19M)(9.47M)(1.9M)(914K)
Acquisitions (Net)953.73M221.47M000
Purchases of Investments(1.51B)(1.42B)(1.07B)(1.49B)(1.01B)
Sales of Investments555.6M1.2B1.45B1.21B1.01B
Other Investing Activities(953.73M)(221.47M)(2.5M)0(34M)
Investing Cash Flow(1.04B)(258.66M)374.65M(280.48M)(31.81M)
Debt Repayment00000
Common Stock Issued213.27M970K62.66M300.7M426.03M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities37.68M37.62M031.29M0
Financing Cash Flow250.95M38.59M62.66M331.98M426.03M
Effect of Forex Changes(11K)(80K)656K(21K)95K
Net Change in Cash(245.52M)(715.88M)177.59M(91.29M)49.3M
Free Cash Flow457.27M(532.93M)(269.85M)(144.68M)(345.93M)

CRISPR Therapeutics AG

NASDAQ:CRSP

Intrinsic Alpha fair value

Locked

Current Price

$40.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.